SCHEMBL25199144

SCHEMBL25199144

O=C(/C=C/c1ccc(O)c(O)c1)OCC=Cc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 5/20 0.67
AKR1B10 O60218 2/20 0.67
AKR1B1 P15121 2/20 0.67
APP P05067 11/20 0.67
CYP3A4 P08684 2/20 0.64
ALOX15 P16050 2/20 0.64
ALOX12 P18054 2/20 0.64
MAPK1 P28482 2/20 0.64
HSD17B10 Q99714 2/20 0.64
ALDH1A1 P00352 2/20 0.64
MAPT P10636 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
TDP1 Q9NUW8 2/20 0.64
ALOX5 P09917 2/20 0.64
KDM4E B2RXH2 1/20 0.64
MEN1 O00255 1/20 0.64
GMNN O75496 1/20 0.64
EGFR P00533 1/20 0.64
LMNA P02545 1/20 0.64
ESR1 P03372 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30448962 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4
SCHEMBL30610038 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4
SCHEMBL20914983 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4
SCHEMBL30431823 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4
SCHEMBL1659848 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4
SCHEMBL20914982 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4
SCHEMBL20914984 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4
SCHEMBL20941431 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4
SCHEMBL20914981 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4
SCHEMBL30449303 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025149378-A1 PROPOLIS EXTRACT WITH ACTIVE FRACTIONS TITRATED INTO BIOACTIVE COMPONENTS AND METHOD OF ITS PRODUCTION APIVITA S.A. (GR) 2025-07-17 WO claimed
WO-2025149378-A1 PROPOLIS EXTRACT WITH ACTIVE FRACTIONS TITRATED INTO BIOACTIVE COMPONENTS AND METHOD OF ITS PRODUCTION APIVITA S.A. (GR) 2025-07-17 WO disclosed
US-20240389587-A1 COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) (FR) 2024-11-28 US disclosed
WO-2023099609-A1 COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) (FR) 2023-06-08 WO disclosed
EP-4186367-A1 COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE) (FR) 2023-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240389587-A1 COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS XBP1, ERN1, ERN2 TTR 3033/4885AKR1B10 2183/4885AKR1B1 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.